Angela Sommers Cormier, PA
Physician Assistant · Land O Lakes, FLNPI 1598067654
Payments from drug & device makers
Across 180 payments — averaging $21.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$546
- AbbVie$352
- Lilly USA, LLC$309
- Novo Nordisk$272
- Xeris Pharmaceuticals, Inc.$269
- Dexcom, Inc.$199
- plus $2K from 26 others
What the payments were for
- Food & beverage$3,793100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 31 | $546 |
| AbbVie | 21 | $352 |
| Lilly USA, LLC | 10 | $309 |
| Novo Nordisk | 13 | $272 |
| Xeris Pharmaceuticals, Inc. | 13 | $269 |
| Dexcom, Inc. | 10 | $199 |
| Bayer | 7 | $179 |
| Corcept Therapeutics | 8 | $164 |
| Sanofi-aventis U.S. LLC | 5 | $157 |
| IBSA Pharma Inc. | 7 | $156 |
| Amgen | 9 | $156 |
| Amryt Pharma Holdings Ltd | 2 | $145 |
| Renalytix AI, Inc. | 6 | $122 |
| Abbott | 5 | $101 |
| Antares Pharma, Inc. | 5 | $91 |
| AstraZeneca | 4 | $83 |
| Boehringer Ingelheim | 3 | $66 |
| Amarin Pharma, Inc. | 3 | $57 |
| Otsuka America Pharmaceutical, Inc. | 1 | $48 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $43 |
| Acerus Pharmaceuticals Corporation | 2 | $40 |
| Amneal Pharmaceuticals LLC | 2 | $31 |
| Merck | 2 | $30 |
| Lifescan, Inc. | 1 | $27 |
| Esperion Therapeutics, Inc. | 1 | $24 |
| Mannkind Corporation | 1 | $23 |
| Medtronic | 1 | $20 |
| Halozyme Inc | 1 | $18 |
| Recordati_rare_diseases_inc. | 1 | $18 |
| Tolmar, Inc. | 1 | $15 |
| Cequr Corporation | 1 | $15 |
| Sequel Med Tech, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,793 in reported general payments places this provider in the 85th percentile of 8,062 physician assistant providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 150 | $149,103 |
| MounjaroTirzepatide | 105 | $137,916 |
| OzempicSemaglutide | 108 | $135,167 |
| EliquisApixaban | 173 | $68,300 |
| JanuviaSitagliptin Phosphate | 105 | $67,199 |
| Tresiba Flextouch U-200Insulin Degludec | 43 | $45,925 |
| TrulicityDulaglutide | 39 | $44,605 |
| FarxigaDapagliflozin Propanediol | 41 | $38,567 |
| RybelsusSemaglutide | 29 | $37,548 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 12 | $33,552 |
| AptiomEslicarbazepine Acetate | 18 | $29,634 |
| MyrbetriqMirabegron | 63 | $27,693 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $23,723 |
| NuedextaDextromethorphan Hbr/Quinidine | 15 | $22,832 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $19,053 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $309 | $182,520144 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $272 | $177,323150 claims |
| Boehringer IngelheimJardiance, Tradjenta | $66 | $168,052191 claims |
| MerckJanuvia, Belsomra | $30 | $74,117120 claims |
| AstraZenecaFarxiga, Symbicort, Brilinta | $83 | $49,88377 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $157 | $14,34914 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $31 | $4,361603 claims |
| AbbVieSynthroid | $352 | $4,12358 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,062 physician assistant providers in Florida.
Other physician assistant in Land O Lakes
- Richard MarshallPort Orange$988K
- Audrey BeckerSt Augustine$689K
- Kevin WilliamsTampa$647K
- Brian BonomoLecanto$559K
- Melissa SingletonOcala$482K
- Reeli ReinuMaitland$427K
- Jeanelle KingMiami$424K
- Risha BellomoOrlando$397K
- Jason BergerClearwater$344K
- Ashley MillerGainesville$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.